Biogen Idec Inc. (now Biogen Inc.) — Q1 2011 Form 10-Q
Period: Three months ended March 31, 2011; unaudited. The filing identifies the registrant as Biogen Idec Inc. The company is a global biotechnology business focused on serious diseases, particularly neurological disorders, with four marketed products: AVONEX, RITUXAN, TYSABRI and FUMADERM.
Financial results
Amounts are in millions of dollars except per-share data and percentages. Comparisons are with Q1 2010.
| Metric | Q1 2011 | Q1 2010 | Change |
|---|---|---|---|
| Total revenue | $1,203.3 | $1,108.9 | +8.5% |
| Product revenue | $907.1 | $824.2 | +10.1% |
| Unconsolidated joint business revenue | $256.1 | $254.9 | +0.5% |
| Operating income | $416.3 | $303.7 | +37.1% |
| Net income attributable to Biogen Idec | $294.3 | $217.4 | +35.4% |
| Diluted EPS | $1.20 | $0.80 | +50.4% |
| Operating margin | 34.6% | 27.4% | +7.2 percentage points |
| Net margin attributable to Biogen Idec | 24.5% | 19.6% | +4.9 percentage points |
| Cash flow from operations (cash flow statement) | $253.6 | $336.9 | -24.7% |
Revenue growth was led by AVONEX, at $642.5 million (+8.4%), and TYSABRI, at $251.4 million (+15.0%). RITUXAN joint-business revenue was essentially flat at $256.1 million: higher U.S. co-promotion profits were offset by declining rest-of-world royalties and lower expense reimbursements. Total costs and expenses fell 2.2% to $787.1 million. R&D declined 4.4% to $293.6 million and SG&A declined 1.7% to $244.5 million, while collaboration profit sharing rose 17.7% to $74.8 million.
At March 31, cash and cash equivalents were $790.7 million and marketable securities totaled $1,323.3 million, for combined financial assets of $2,114.0 million. Total borrowings were $1,200.4 million; the company reported no significant change in borrowings from year-end. Current assets were $2,628.3 million, current liabilities $978.8 million and working capital $1,649.5 million. Total assets were $8,293.5 million and total liabilities $2,619.2 million.
Changes, outlook and management commentary
- Management said its 2010 restructuring and organizational initiatives were intended to improve efficiency. It expects approximately $300 million of annual operating expense savings beginning in the second half of 2011, with some savings potentially offset by growth investments. It expects total restructuring charges of approximately $110 million; $16.6 million was recorded in Q1 2011, and substantially all remaining charges are expected by year-end.
- Management expects higher cost of sales in 2011, citing increased contract manufacturing activity and production costs beginning in the second half. R&D spending is expected to remain focused on BG-12, hemophilia programs, MS and neurodegenerative disease candidates.
- In April 2011, Biogen Idec reported positive top-line results from the first pivotal Phase 3 BG-12 trial, DEFINE; the second trial, CONFIRM, was ongoing, with results expected in the second half of 2011. The FDA had rescinded BG-12’s fast-track designation. These are post-quarter developments, not Q1 results.
- TYSABRI revenue grew, but PML risk, safety-label changes, patient risk stratification and competition may constrain growth. Regulators continued to monitor PML risk; the filing describes April 2011 label and authorization developments.
- The company cited competition, possible biosimilars, healthcare cost controls and pricing pressure, foreign exchange, and delayed collections in parts of Europe as risks. Receivables in Italy, Spain and Portugal totaled approximately $283.9 million, of which approximately $70 million had been outstanding for more than one year.
- Contingencies include Massachusetts tax assessments totaling $142.4 million, which the company is contesting, and multiple patent disputes. The filing notes potential RITUXAN royalty exposure in Hoechst/Sanofi matters; in a separate Sanofi patent action, the court granted summary judgment of non-infringement, with other claims still pending. The company could not estimate the potential loss in a TYSABRI-related Novartis patent suit.
- The company repurchased approximately 2.8 million shares for $195.3 million in Q1 under a new authorization for up to 20 million shares. It reported $87 million of uncertain-tax-position liabilities, including approximately $30.1 million expected to be paid within six months.
- No formal full-year revenue or earnings guidance is provided in the supplied filing text. Management said available funds, operating cash flows and potential financing resources should be sufficient for foreseeable requirements.
Investor items to verify
- Cash-flow figure: the cash flow statement and the MD&A cash-flow discussion report Q1 operating cash flow of $253.6 million, while the executive summary states $272.6 million. The filing text does not reconcile this difference.
- Progress and results of CONFIRM and the regulatory, commercial and data-protection outlook for BG-12, including any contingent milestone obligations.
- TYSABRI sales trends, PML cases and risk-management developments, and the effect of safety labeling and competition on prescribing.
- Collection timing and recoverability of European government-related receivables, particularly the aged balances in Italy, Spain and Portugal.
- Restructuring charges and realization of the stated $300 million annual savings, alongside planned spending and manufacturing costs.
- Outcomes and potential financial effects of the Massachusetts tax dispute and patent litigation, including RITUXAN and TYSABRI matters.